OSH ALERT - Labaton Sucharow Notifies Oak Street Health, Inc. Investors of the Filing of a Class Action Lawsuit

Labaton Sucharow, a nationally ranked and award-winning shareholder rights firm, announces a class action lawsuit has been filed against Oak Street Health, Inc. (NYSE:OSH) on behalf of shareholders who purchased or otherwise acquired Oak Street securities between August 6, 2020, and November 8, 2021, (the "Class Period"). Investors are encouraged to contact the firm before March 14, 2022.

In Oak Street Health's Q3 update on Monday, November 8, 2021, the Company revealed that the U.S. Department of Justice (DOJ) is investigating whether it may have violated the False Claims Act and said the DOJ has requested documents and information related to Oak Street providing free transportation to federal healthcare beneficiaries and related to its relationships with third-party marketing agents.

On this news, the stock fell as much as 22% on Tuesday, November 9, 2021, the steepest intraday decline on record for Oak Street, which first sold shares to the public last year.

If you purchased or otherwise acquired OSH during the Class Period, click here to participate.

If you want to receive additional information and protect your investments free of charge, please contact David J. Schwartz using the toll-free number (800) 321-0476 or via email at david@labaton.com.

About the Firm

Labaton Sucharow LLP is one of the world's leading complex litigation firms representing clients in securities, antitrust, corporate governance and shareholder rights, and consumer cybersecurity and data privacy litigation. Labaton Sucharow has been recognized for its excellence by the courts and peers, and it is consistently ranked in leading industry publications. Offices are located in New York, NY, Wilmington, DE, and Washington, D.C. More information about Labaton Sucharow is available at labaton.com.

Contacts

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.